Clinical Trials Logo

brca2 Mutation Carrier clinical trials

View clinical trials related to brca2 Mutation Carrier.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01233505 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Start date: October 2010
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and the best dose of veliparib when given together with capecitabine and oxaliplatin in treating patients with advanced solid tumors. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving veliparib together with capecitabine and oxaliplatin may kill more tumor cells.